Intellikine, Inc. Appoints William Rohn to its Board of Directors
Published: Feb 23, 2010
LA JOLLA, Calif., Feb. 23 /PRNewswire/ -- Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company's board of directors.
"We are delighted to welcome Bill Rohn to Intellikine's board of directors," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine. "His strategic insights and experience in growing biotechnology companies, including his experience transitioning IDEC from a development stage company to a very successful commercial enterprise, will be invaluable to Intellikine as we seek to advance our growing pipeline of drugs against the PI3K/mTOR pathway."
Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseases. Other programs include PI3K-delta/gamma dual-selective inhibitors for oncology, PI3K-alpha/beta selective inhibitors for oncology, as well as other isoform-selective inhibitors. Intellikine has raised $41 million from an outstanding group of life science investors including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital. In addition, Intellikine has a commitment, subject to fulfillment of certain conditions, for another $22.5 million in equity financing from its current investors. For more information, please visit the company's website at www.intellikine.com.